Private Wealth Advisors Inc. cut its holdings in shares of Medtronic plc. (NYSE:MDT) by 2.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,146 shares of the medical technology company’s stock after selling 649 shares during the quarter. Private Wealth Advisors Inc.’s holdings in Medtronic were worth $2,111,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of MDT. Arcus Capital Partners LLC grew its position in shares of Medtronic by 0.8% in the 2nd quarter. Arcus Capital Partners LLC now owns 3,249 shares of the medical technology company’s stock worth $288,000 after acquiring an additional 25 shares in the last quarter. Fiera Capital Corp grew its position in shares of Medtronic by 0.5% in the 2nd quarter. Fiera Capital Corp now owns 6,832 shares of the medical technology company’s stock worth $606,000 after acquiring an additional 37 shares in the last quarter. Chemical Bank grew its position in shares of Medtronic by 0.4% in the 2nd quarter. Chemical Bank now owns 11,623 shares of the medical technology company’s stock worth $1,031,000 after acquiring an additional 46 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its position in shares of Medtronic by 0.3% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 28,284 shares of the medical technology company’s stock worth $2,510,000 after acquiring an additional 72 shares in the last quarter. Finally, Miles Capital Inc. grew its position in shares of Medtronic by 3.4% in the 2nd quarter. Miles Capital Inc. now owns 2,581 shares of the medical technology company’s stock worth $229,000 after acquiring an additional 86 shares in the last quarter. Institutional investors own 79.83% of the company’s stock.
Medtronic plc. (NYSE:MDT) opened at $80.39 on Friday. Medtronic plc. has a 12-month low of $76.51 and a 12-month high of $89.72. The stock has a market capitalization of $108,980.00, a P/E ratio of 22.09, a P/E/G ratio of 2.23 and a beta of 0.93. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.05 and a current ratio of 2.43.
Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 20th. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.01. Medtronic had a return on equity of 12.65% and a net margin of 9.44%. The business had revenue of $7.37 billion during the quarter, compared to analyst estimates of $7.20 billion. During the same quarter in the previous year, the firm posted $1.12 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. equities analysts forecast that Medtronic plc. will post 4.76 earnings per share for the current fiscal year.
Several research analysts have recently commented on MDT shares. Bank of America upgraded Medtronic from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Oppenheimer reiterated a “buy” rating on shares of Medtronic in a research report on Thursday, December 21st. SunTrust Banks set a $92.00 target price on Medtronic and gave the stock a “buy” rating in a research report on Sunday, November 19th. Needham & Company LLC reiterated a “buy” rating and issued a $94.00 target price on shares of Medtronic in a research report on Thursday, November 9th. Finally, Cowen reiterated a “buy” rating and issued a $95.00 target price on shares of Medtronic in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $90.85.
In related news, EVP Hooman Hakami sold 26,158 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $85.00, for a total transaction of $2,223,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Richard Kuntz sold 78,526 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $86.21, for a total value of $6,769,726.46. Following the transaction, the vice president now owns 149,761 shares of the company’s stock, valued at approximately $12,910,895.81. The disclosure for this sale can be found here. Insiders have sold a total of 120,684 shares of company stock valued at $10,318,276 in the last 90 days. Insiders own 0.31% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Private Wealth Advisors Inc. Has $2.11 Million Position in Medtronic plc. (MDT)” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://transcriptdaily.com/2018/02/24/private-wealth-advisors-inc-has-2-11-million-position-in-medtronic-plc-mdt.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.